Company news

Acrux Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Acrux Investor Presentation - September 2021

September 1, 2021

US Launch - Testosterone Topical Solution

August 25, 2021

Appendix 4E and Financial Report

August 25, 2021

Acrux receives third FDA ANDA approval

July 27, 2021

Acrux Receives FDA Approval - Generic Efinaconazole Solution

June 22, 2021

Acrux confirms patent challenge

June 7, 2021

Acruxs fourth generic dossier accepted by FDA for review

April 15, 2021

Acrux Investor Presentation

February 24, 2021

Appendix 4D and Half Year Accounts - for the 31 Dec ac

February 24, 2021

Share Purchase Plan Closes Oversubscribed

February 2, 2021

Acrux Receives FDA Approval - Generic Testosterone Solution

January 11, 2021

Acrux Ltd Share Purchase Plan Offer Booklet

January 7, 2021

Acrux Raises $7.8m Via Placement and Announces SPP

December 20, 2020

Acrux Signs Licensing Agreement with Dash Pharmaceuticals

October 11, 2020

Appendix 4E and Full Year Statutory Accounts

August 24, 2020

Acrux Signs Licensing Agreement with Harris Pharmaceutical

August 10, 2020

Acrux Signs Co-Development Agreement With Amring

June 17, 2020

Acrux Signs Licensing Agreement With TruPharma

May 28, 2020

Appendix 4D and Half Year Financial Report

February 25, 2020

Receipt of first R&D Tax Incentive Rebate

October 24, 2019

Acrux Ltd Investor Presentation and Full Year Results

August 26, 2019

Appendix 4E & Full Year Statutory Accounts

August 23, 2019

Jublia Patent Litigation Settlement

April 3, 2019

Appendix 4D and Half-Year Financial Report to 31 Dec 2018

February 21, 2019

Acrux Receives $2.057m R&D Tax Incentive Rebate

January 21, 2019

Acrux has second generic dossier accepted for review by FDA

October 16, 2018

Acrux confirms patent challenge for generic of efinaconazole

September 23, 2018

Appendix 4E and 2018 Financial Report

August 16, 2018

Acrux Submits First-To-File Generic of Jublia

August 2, 2018

Appendix 4D and Half-Year Report to 31 December 2017

February 20, 2018

Axiron Net Sales Quarter to December 2017

January 31, 2018

Axiron Patents Appeal Decision

November 22, 2017

Axiron Net Sales Quarter to September 2017

October 24, 2017

Axiron License Agreement Terminated

September 5, 2017

Appendix 4E and 2017 Financial Report

August 22, 2017

Teva Launches Generic Version of Axiron in United States

August 21, 2017

Axiron Net Sales Quarter to 30 June 2017

July 25, 2017

Axiron Generic Launched In The United States

July 6, 2017

Institution of IPR Proceeding Against Key Jublia Patent

May 2, 2017

Axiron Net Sales Quarter to 31 March 2017

April 25, 2017

Appendix 4D and Half Year Report to 31 December 2016

February 17, 2017

Axiron Net Sales, Quarter to December2016

January 31, 2017

S&P DJ Indices Announces March Quarterly Review

November 7, 2016

European approvals and milestone payments for Lenzetto

November 6, 2016

IPR Petition Filed Against Key Jublia Patent

November 2, 2016

New intellectual property application for onychomycosis

November 1, 2016

Axiron Net Sales, Quarter to September 2016

October 25, 2016

Acrux announces 2016 financial results

August 24, 2016

Acrux announces court ruling on Axiron patent families

August 23, 2016

Axiron Net Sales, quarter to June 2016

July 26, 2016

← Newer news releases · Older news releases →

Decks

The 5 newest of 59 decks. Every deck is listed under its year.